Takimura Hideyuki, Taniguchi Rintaro, Tsuzuki Ippei, Tajima Emi, Yamaguchi Yukihiro, Kawano Mami, Takimura Yukako, Nishio Satoru, Nakano Masatsugu, Tsukahara Reiko
Department of Cardiology, Tokyo General Hospital, Tokyo, Japan.
Department of Cardiology, Tokyo General Hospital, Tokyo, Japan.
Int J Cardiol. 2023 May 15;379:89-95. doi: 10.1016/j.ijcard.2023.03.034. Epub 2023 Mar 17.
Early decongestion with diuretics could improve clinical outcomes. This study aimed to examine the impact of the time-to-target rate of urine volume (T2TUV) concept on the outcome of acute decompensated heart failure (ADHF).
This multicenter retrospective study included 1670 patients with ADHF who received diuretics within 24 h of admission. T2TUV was defined as the time from admission to the rate of urine volume of 100 ml/h. The primary outcomes were in-hospital death, mortality, and re-hospitalization for 1 year.
A total of 789 patients met the inclusion criteria (T2TUV on day 1, n = 248; day 2-3, n = 172; no target rate UV, n = 369). In-hospital mortality in the day 1 group was significantly lower (2.7% vs. 5.9% vs. 11.1%; p < 0.001) than that of other groups. The mortality and re-hospitalization for 1 year in the day 1 group was significantly lower (event-free rate: 67.7% vs. 54.1% vs. 56.9%; log-lank p = 0.004) than that of other groups. In multivariate analysis, predictors of T2TUV at day 1 were age (odds ratio [OR]: 1.02, 95% confidence interval [CI]: 1.01-1.04, p = 0.007), previous hospitalized heart failure (OR: 1.47, 95% CI: [1.03-2.12], p = 0.03), N-terminal-pro B type natriuretic peptide per 1000 pg/ml (OR: 1.02, 95% CI: 1.01-1.04, p = 0.007), carperitide (OR: 0.69, 95% CI: 0.48-0.99, p = 0.05), and early administration of tolvaptan (OR: 0.6, 95% CI: 0.42-0.85, p = 0.004).
T2TUV of less than day 1 was associated with lower in-hospital mortality and decreased mortality and re-hospitalization at 1 year.
早期使用利尿剂减轻充血可改善临床结局。本研究旨在探讨达到目标尿量率时间(T2TUV)概念对急性失代偿性心力衰竭(ADHF)结局的影响。
这项多中心回顾性研究纳入了1670例ADHF患者,这些患者在入院24小时内接受了利尿剂治疗。T2TUV定义为从入院到尿量达到100 ml/h的时间。主要结局为住院死亡、死亡率和1年内再住院情况。
共有789例患者符合纳入标准(第1天达到T2TUV,n = 248;第2 - 3天,n = 172;未达到目标尿量率,n = 369)。第1天组的住院死亡率显著低于其他组(2.7%对5.9%对11.1%;p < 0.001)。第1天组的1年死亡率和再住院率显著低于其他组(无事件发生率:67.7%对54.1%对56.9%;log-rank p = 0.004)。在多因素分析中,第1天达到T2TUV的预测因素为年龄(比值比[OR]:1.02,95%置信区间[CI]:1.01 - 1.04,p = 0.007)、既往因心力衰竭住院(OR:1.47,95% CI:[1.03 - 2.12],p = 0.03)、每1000 pg/ml的N末端B型利钠肽原(OR:1.02,95% CI:1.01 - 1.04,p = 0.007)、卡培立肽(OR:0.69,95% CI:0.48 - 0.99,p = 0.05)以及早期使用托伐普坦(OR:0.6,95% CI:0.42 - 0.85,p = 0.004)。
T2TUV小于1天与较低的住院死亡率以及1年时死亡率和再住院率降低相关。